GSK - Ticker AI Digest

GSK 06:01

GSK plc

FDA to review gonorrhea indication for gepotidacin

Open AI Digest

Go Back To AI Charts

Return to today’s catalyst cards, chart beacons and AI charts.

**Summary**

GSK plc announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental New Drug Application for **gepotidacin**, an oral treatment for **uncomplicated urogenital gonorrhea** in patients aged 12 and older. The decision is expected by **December 2025**. This submission is supported by positive Phase III data from the **EAGLE-1 trial**, which demonstrated gepotidacins non-inferiority to the current standard injectable treatment (ceftriaxone plus azithromycin), with a **92.6% success rate** at the urogenital site.

Gonorrhea, caused by *Neisseria gonorrhoeae*, is a priority pathogen for the **World Health Organization (WHO)** and an urgent public health threat due to rising antimicrobial resistance. Gepotidacin, a first-in-class antibiotic, offers a novel mechanism of action and addresses the need for new oral treatment options, as current therapies are injectable and may not be suitable for all patients.

If approved, gepotidacin would be the **first oral treatment** for gonorrhea in the U.S., providing a significant advancement in managing this sexually transmitted infection. The drug was previously approved in March 2025 under the name **Blujepa** for uncomplicated urinary tract infections (uUTI). Regulatory reviews for uUTI are also ongoing in the **UK and Australia**.

GSK’s development of gepotidacin has been partially funded by the **U.S. Department of Health and Human Services** and the **Department of Defense**, highlighting its importance in addressing antimicrobial resistance and public health needs.

Go Back To AI Charts

GSK 06:01

GSK plc

CureVac/BioNTech mRNA patent litigation settlement

Open AI Digest

Go Back To AI Charts

Return to today’s catalyst cards, chart beacons and AI charts.

GSK plc announced a settlement in the mRNA patent litigation between CureVac and BioNTech, effective August 8, 2025. Key terms include

1. **Upfront Payment**CureVac will pay GSK $370 million, with $320 million in cash and the remainder attributed to reduced royalties on GSKs future mRNA products.

2. **Royalties**GSK will receive a 1% royalty on U.S. sales of Pfizer/BioNTech’s influenza, COVID-19, and combination mRNA vaccines from 2025 onward.

3. **Conditional Benefits**If BioNTech’s acquisition of CureVac closes, GSK will receive an additional $130 million in cash and 1% royalties on non-U.S. sales, along with reduced milestones and royalties on its own mRNA products outside the U.S.

4. **Financial Impact**The upfront payment will be recorded as other operating income in Q3 2025, with future royalties reflected in total and core results.

5. **Ongoing Litigation**GSK will continue its separate patent infringement litigation against BioNTech and Pfizer in the U.S. and Europe.

6. **Tender Agreement**GSK agreed to tender its 16.6 million CureVac shares in the upcoming acquisition offer.

This settlement aligns with GSK’s existing license agreement with CureVac and does not affect its ongoing legal actions against Pfizer and BioNTech.

Go Back To AI Charts

GSK 06:01

GSK plc

FDA to review gonorrhea indication for gepotidacin

Open AI Digest

Go Back To AI Charts

Return to today’s catalyst cards, chart beacons and AI charts.

**Summary**

GSK plc announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental New Drug Application for **gepotidacin**, an oral treatment for **uncomplicated urogenital gonorrhea** in patients aged 12 and older. The decision is expected by **December 2025**. This submission is supported by positive Phase III data from the **EAGLE-1 trial**, which demonstrated gepotidacins non-inferiority to the current standard injectable treatment (ceftriaxone plus azithromycin), with a **92.6% success rate** at the urogenital site.

Gonorrhea, caused by *Neisseria gonorrhoeae*, is a priority pathogen for the **World Health Organization (WHO)** and an urgent public health threat due to rising antimicrobial resistance. Gepotidacin, a first-in-class antibiotic, offers a novel mechanism of action and addresses the need for new oral treatment options, as current therapies are injectable and may not be suitable for all patients.

If approved, gepotidacin would be the **first oral treatment** for gonorrhea in the U.S., providing a significant advancement in managing this sexually transmitted infection. The drug was previously approved in March 2025 under the name **Blujepa** for uncomplicated urinary tract infections (uUTI). Regulatory reviews for uUTI are also ongoing in the **UK and Australia**.

GSK’s development of gepotidacin has been partially funded by the **U.S. Department of Health and Human Services** and the **Department of Defense**, highlighting its importance in addressing antimicrobial resistance and public health needs.

Go Back To AI Charts

GSK 06:01

GSK plc

CureVac/BioNTech mRNA patent litigation settlement

Open AI Digest

Go Back To AI Charts

Return to today’s catalyst cards, chart beacons and AI charts.

GSK plc announced a settlement in the mRNA patent litigation between CureVac and BioNTech, effective August 8, 2025. Key terms include

1. **Upfront Payment**CureVac will pay GSK $370 million, with $320 million in cash and the remainder attributed to reduced royalties on GSKs future mRNA products.

2. **Royalties**GSK will receive a 1% royalty on U.S. sales of Pfizer/BioNTech’s influenza, COVID-19, and combination mRNA vaccines from 2025 onward.

3. **Conditional Benefits**If BioNTech’s acquisition of CureVac closes, GSK will receive an additional $130 million in cash and 1% royalties on non-U.S. sales, along with reduced milestones and royalties on its own mRNA products outside the U.S.

4. **Financial Impact**The upfront payment will be recorded as other operating income in Q3 2025, with future royalties reflected in total and core results.

5. **Ongoing Litigation**GSK will continue its separate patent infringement litigation against BioNTech and Pfizer in the U.S. and Europe.

6. **Tender Agreement**GSK agreed to tender its 16.6 million CureVac shares in the upcoming acquisition offer.

This settlement aligns with GSK’s existing license agreement with CureVac and does not affect its ongoing legal actions against Pfizer and BioNTech.

Go Back To AI Charts